Assessment of clinicopathological and prognostic relevance of BMI‐1 in patients with colorectal cancer: A meta‐analysis. (2nd November 2020)

• Record Type: Journal Article
• Authors: Pourjafar, Mona; Samadi, Pouria; Karami, Manoochehr; Najafi, Rezvan
• Is Part Of: Biotechnology and applied biochemistry. Volume 68:Number 6(2021)
• Page Start: 1313
• Page End: 1322
• Publication Date: 2020-11-02
• Subjects: B‐cell‐specific Moloney leukemia virus insertion site 1 -- colorectal neoplasms -- prognosis; Biotechnology -- Periodicals; Biochemical engineering -- Periodicals; Biochemistry -- Periodicals; Biochemistry -- Periodicals; Genetic Techniques -- Periodicals; Microbiological Techniques -- Periodicals; 660.6
• DOI: 10.1002/bab.2053
• Languages: English
• ISSNs: 0885-4513

Abstract

Abstract: B‐cell‐specific Moloney leukemia virus insertion site 1 (BMI‐1) is one of the stemness markers. The prognostic and clinicopathological effects of BMI‐1 expression in colorectal cancer (CRC) have been in dispute with different studies. Eligible studies were retrieved from international databases up to December 2019. Studies with a relationship between the clinicopathological and prognostic value of CRC patients with BMI‐1 expression were selected. The correlations in the random‐effect model were evaluated using the hazard ratios, odds ratio, and 95% confidence intervals (CIs). A total of nine studies comprising Asian cases (seven studies) and European cases (two studies) covering 1, 294 samples of CRC were included for this meta‐analysis. The analysis suggested that in Asian cases, increased expression of BMI‐1 was associated with poor overall survival (OS) and death‐free survival, whereas in European populations, high expression of BMI‐1 was associated with better OS. Also, overexpression of BMI‐1 in the Asian population was associated with the tumor size, distant metastasis, and patient's gender and age. Results suggested that high expression of BMI‐1 can be involved in the progression and invasion of CRC, and so its inhibitor‐based therapies could be used to prevent the progression of CRC. Abstract : The prognostic effect of B‐cell‐specific Moloney leukemia virus insertion site 1 (Bmi‐1) in patients with colorectal cancer (CRC) remains controversial. We thus performed a meta‐analysis to reveal the correlation between Bmi‐1 with clinical features and overall survival (OS) in CRC patients.